Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

Table 4

Table showing the studies using metronomic regimens in hepatocellular cancer. UFT, Tegafur-5 FU.

Author	Treatment	N	Patient type	SD	PR	CR	ORR	TTP	PFS	OS
Hsu, 2010	Sorafenib 400 mg bid; UFT 125mg/m2	53	Untreated, Child-Pugh class A	26; (49%)	4; (8%)				3.7 m	7.4 m
Boige, 2012	Bevacizumab 5 mg/kg or 10 mg/kg q14d	43	Advanced	N/A	6; (14.0%)	N/A	14.0%
Shao, 2012	Thalidomide 100 mg bid; UFT 125mg/m2	43	Untreated,				9%		1.9 m
Woo, 2012	(Into the hepatic artery); Epirubicin 30 mg/m2 q28d; Cisplatin 15mg/m2 q21d; 5-FU 50 mg/m2 q21d	30	Portal vein thrombosis		6; (20.0%)			63 d		63 d
Brandi, 2013	Capecitabine 500 mg bid	59	Untreated	30	1	2			6.03 m	14.47 m
		31	Sorafenib refractory	10	N/A	N/A			3.27 m	9.77 m
Granito, 2015	Capecitabine 500 mg bid	26	Sorafenib refractory					4 m		8 m